GS0411: Educational services, namely, conducting educational programs in the fields of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders and treatment and patient support options for these conditions
DM0000: The mark consists of the trademark "YARTEMLEASSURE" in capital letters, with "YARTEMLEA" in purple, and "SSURE" in gold, in which the second letters "E" and "A" are connected with a thick gold curving line that goes from the middle horizontal line in the "E" and crosses the middle of the letter "A" and serves as its crossbar. The second letter "A" also features a gold sloping line to the right of and paralleling the right leg of that letter. The phrase "PATIENT SUPPORT PROGRAM" is below in a purple parallelogram with rounded upper right and lower left corners. The color white in the wording "PATIENT SUPPORT PROGRAM" indicates background and is not part of the mark.
GS0161: Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support
PM0001: YARTEM LEASSURE PATIENT SUPPORT PROGRAM; YARTEM LEISURE PATIENT SUPPORT PROGRAM
GS0361: Providing a website featuring financial information regarding medical benefits and reimbursements available for medical expenses related thereto; insurance services, namely, benefits verification in the nature of insurance claims administration; and providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders
CC0000: The color(s) purple and gold is/are claimed as a feature of the mark.
GS0351: Promoting awareness of patient support offerings for endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; business administration of reimbursement and medical benefit information for endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders and their treatment; and business administrative services for medical referrals
D10000: "PATIENT SUPPORT PROGRAM"
Case File Event Statements
2/5/2024 - a year ago
37 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDType:MAB6
2/5/2024 - a year ago
36 - ABANDONMENT - NO USE STATEMENT FILEDType:ABN6
6/14/2023 - 2 years ago
35 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
6/12/2023 - 2 years ago
34 - SOU EXTENSION 2 GRANTEDType:EX2G
6/12/2023 - 2 years ago
33 - SOU EXTENSION 2 FILEDType:EXT2
6/12/2023 - 2 years ago
32 - SOU TEAS EXTENSION RECEIVEDType:EEXT
10/21/2022 - 3 years ago
31 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
10/19/2022 - 3 years ago
30 - SOU EXTENSION 1 GRANTEDType:EX1G
10/19/2022 - 3 years ago
29 - SOU EXTENSION 1 FILEDType:EXT1
10/19/2022 - 3 years ago
28 - SOU TEAS EXTENSION RECEIVEDType:EEXT
7/5/2022 - 3 years ago
27 - NOA E-MAILED - SOU REQUIRED FROM APPLICANTType:NOAM
5/10/2022 - 3 years ago
26 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILEDType:NPUB
5/10/2022 - 3 years ago
25 - PUBLISHED FOR OPPOSITIONType:PUBO
4/20/2022 - 3 years ago
24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILEDType:NONP
4/6/2022 - 3 years ago
23 - LAW OFFICE PUBLICATION REVIEW COMPLETEDType:PREV
4/2/2022 - 3 years ago
22 - APPROVED FOR PUB - PRINCIPAL REGISTERType:CNSA
4/1/2022 - 3 years ago
21 - TEAS/EMAIL CORRESPONDENCE ENTEREDType:TEME
3/31/2022 - 3 years ago
20 - CORRESPONDENCE RECEIVED IN LAW OFFICEType:CRFA
3/31/2022 - 3 years ago
19 - TEAS RESPONSE TO OFFICE ACTION RECEIVEDType:TROA
3/23/2022 - 3 years ago
18 - NOTIFICATION OF NON-FINAL ACTION E-MAILEDType:GNRN
3/23/2022 - 3 years ago
17 - NON-FINAL ACTION E-MAILEDType:GNRT
3/23/2022 - 3 years ago
16 - NON-FINAL ACTION WRITTENType:CNRT
3/2/2022 - 3 years ago
15 - PREVIOUS ALLOWANCE COUNT WITHDRAWNType:ZZZX
2/22/2022 - 3 years ago
14 - WITHDRAWN FROM PUB - OG REVIEW QUERYType:PBCR
2/10/2022 - 3 years ago
13 - APPROVED FOR PUB - PRINCIPAL REGISTERType:CNSA
2/10/2022 - 3 years ago
12 - EXAMINER'S AMENDMENT ENTEREDType:XAEC
2/9/2022 - 3 years ago
11 - ASSIGNED TO LIEType:ALIE
2/9/2022 - 3 years ago
10 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILEDType:GNEN